This person is a member of Sanger Institute Alumni.
After five years at the Wellcome Sanger Institute working on the identification of new drug combinations for anti-cancer therapies I have now moved on to pursue oncology research in industry.
Within the Translational Cancer Genomics group, Patricia works on large-scale combination drug screens in cancer cell lines to establish a combination drug screen analysis framework and to identify novel cancer therapies and genetic biomarkers of synergy.
From 2016-2021 Patricia was part of the Translational Cancer Genomics team of Dr Garnett at the Wellcome Sanger Institute. She led the generation and analysis of large scale drug combination data sets and established a robust framework to evaluate drug interactions of two-drug combinations screened in pan-cancer (>750 cancer cell lines) and tissue-specific (breast, colorectal and pancreas) settings.
Patricia led several international collaborations with academic and industry partners, including a collaboration with the pharmaceutical partner AstraZeneca.
Patricia’s expertise is in molecular cell biology, cancer genetics, high-throughput chemical screens and anti-cancer therapeutics. She is experienced in laboratory work and computational analysis of large-scale drug screening data. Patricia is passionate about translational cancer research and her research is driven by the desire to improve our understanding of cancer biology and genetics in order to develop new anti-cancer therapeutics.
Staff Scientist at the Wellcome Sanger Institute
Postdoctoral Fellow at the Wellcome Sanger Institute
PhD, University of Zurich, Switzerland and University Children's Hospital Zurich, Switzerland
MSc Molecular Medicine, Imperial College London, UK
BSc Molecular Life Sciences, University of Hamburg, Germany